S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.00 (-2.22%)
AAPL   164.68 (-1.41%)
MSFT   398.93 (-1.32%)
META   479.10 (-4.52%)
GOOGL   153.30 (-1.74%)
AMZN   173.78 (-3.04%)
TSLA   147.07 (-1.91%)
NVDA   771.38 (-8.90%)
AMD   146.09 (-5.80%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.07 (+0.08%)
MU   106.22 (-5.10%)
GE   148.18 (-3.11%)
CGC   8.00 (+2.17%)
DIS   112.10 (-0.29%)
AMC   3.19 (+9.25%)
PFE   25.91 (+2.05%)
PYPL   61.83 (-0.43%)
XOM   119.74 (+1.03%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.00 (-2.22%)
AAPL   164.68 (-1.41%)
MSFT   398.93 (-1.32%)
META   479.10 (-4.52%)
GOOGL   153.30 (-1.74%)
AMZN   173.78 (-3.04%)
TSLA   147.07 (-1.91%)
NVDA   771.38 (-8.90%)
AMD   146.09 (-5.80%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.07 (+0.08%)
MU   106.22 (-5.10%)
GE   148.18 (-3.11%)
CGC   8.00 (+2.17%)
DIS   112.10 (-0.29%)
AMC   3.19 (+9.25%)
PFE   25.91 (+2.05%)
PYPL   61.83 (-0.43%)
XOM   119.74 (+1.03%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.00 (-2.22%)
AAPL   164.68 (-1.41%)
MSFT   398.93 (-1.32%)
META   479.10 (-4.52%)
GOOGL   153.30 (-1.74%)
AMZN   173.78 (-3.04%)
TSLA   147.07 (-1.91%)
NVDA   771.38 (-8.90%)
AMD   146.09 (-5.80%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.07 (+0.08%)
MU   106.22 (-5.10%)
GE   148.18 (-3.11%)
CGC   8.00 (+2.17%)
DIS   112.10 (-0.29%)
AMC   3.19 (+9.25%)
PFE   25.91 (+2.05%)
PYPL   61.83 (-0.43%)
XOM   119.74 (+1.03%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.00 (-2.22%)
AAPL   164.68 (-1.41%)
MSFT   398.93 (-1.32%)
META   479.10 (-4.52%)
GOOGL   153.30 (-1.74%)
AMZN   173.78 (-3.04%)
TSLA   147.07 (-1.91%)
NVDA   771.38 (-8.90%)
AMD   146.09 (-5.80%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.07 (+0.08%)
MU   106.22 (-5.10%)
GE   148.18 (-3.11%)
CGC   8.00 (+2.17%)
DIS   112.10 (-0.29%)
AMC   3.19 (+9.25%)
PFE   25.91 (+2.05%)
PYPL   61.83 (-0.43%)
XOM   119.74 (+1.03%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$11.90
-3.6%
$13.47
$5.65
$17.16
$2.55B0.914.68 million shs3.40 million shs
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$13.50
-2.0%
$15.13
$11.03
$21.22
$1.72B1.1896,865 shs367,973 shs
Nutex Health Inc. stock logo
NUTX
Nutex Health
$0.72
+9.8%
$1.45
$0.50
$10.92
$35.77M0.44237,789 shs814,543 shs
Vericel Co. stock logo
VCEL
Vericel
$42.87
-2.3%
$47.64
$29.24
$53.05
$2.07B1.71550,870 shs226,977 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-0.32%-15.33%-21.10%+48.32%+10.28%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
+0.66%-5.17%-6.45%-12.46%-14.37%
Nutex Health Inc. stock logo
NUTX
Nutex Health
-0.36%-12.69%-56.44%-77.30%-93.73%
Vericel Co. stock logo
VCEL
Vericel
-5.19%-9.98%-3.88%+10.56%+39.64%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
3.2922 of 5 stars
3.32.00.00.02.44.21.9
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
1.9438 of 5 stars
3.42.00.00.02.02.50.6
Nutex Health Inc. stock logo
NUTX
Nutex Health
2.6874 of 5 stars
3.55.00.00.01.61.70.6
Vericel Co. stock logo
VCEL
Vericel
0.5927 of 5 stars
1.51.00.00.02.80.81.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.62
Moderate Buy$14.8524.76% Upside
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2.80
Moderate Buy$19.5044.44% Upside
Nutex Health Inc. stock logo
NUTX
Nutex Health
3.00
Buy$15.001,985.07% Upside
Vericel Co. stock logo
VCEL
Vericel
3.00
Buy$46.408.23% Upside

Current Analyst Ratings

Latest NEO, HIMS, VCEL, and NUTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$17.00 ➝ $15.00
4/10/2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$20.00
4/10/2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$20.00
3/26/2024
Vericel Co. stock logo
VCEL
Vericel
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00
3/1/2024
Vericel Co. stock logo
VCEL
Vericel
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$51.00 ➝ $54.00
3/1/2024
Vericel Co. stock logo
VCEL
Vericel
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$46.00 ➝ $53.00
2/28/2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Imperial Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeIn-Line ➝ Outperform$16.00
2/27/2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $16.00
2/27/2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $17.00
2/27/2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$9.00 ➝ $11.00
2/27/2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$10.00 ➝ $13.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$872M2.92N/AN/A$1.61 per share7.39
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$591.64M2.91$0.28 per share48.46$7.39 per share1.83
Nutex Health Inc. stock logo
NUTX
Nutex Health
$247.65M0.14N/AN/A$1.77 per share0.41
Vericel Co. stock logo
VCEL
Vericel
$197.52M10.50$0.02 per share2,625.13$4.73 per share9.06

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$23.55M-$0.11N/A51.74N/A-2.70%-7.21%-5.81%5/6/2024 (Confirmed)
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$87.97M-$0.70N/AN/AN/A-14.87%-4.13%-2.33%4/30/2024 (Confirmed)
Nutex Health Inc. stock logo
NUTX
Nutex Health
-$45.79M-$1.20N/AN/A-18.49%-45.58%-10.50%5/20/2024 (Estimated)
Vericel Co. stock logo
VCEL
Vericel
-$3.18M-$0.09N/A85.74N/A-1.61%-1.55%-1.02%5/8/2024 (Estimated)

Latest NEO, HIMS, VCEL, and NUTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.0160N/A-$0.0160N/AN/AN/A  
4/30/2024N/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$0.0270N/A+$0.0270N/AN/AN/A  
2/29/2024Q4 2023
Vericel Co. stock logo
VCEL
Vericel
$0.18$0.26+$0.08$0.26$64.28 million$65.00 million    
2/26/2024Q4 2023
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$0.02$0.01+$0.03$0.01$245.84 million$246.60 million      
2/20/2024Q4 2023
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$0.07-$0.02+$0.05$0.07$152.90 million$155.55 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
N/AN/AN/AN/AN/A
Nutex Health Inc. stock logo
NUTX
Nutex Health
N/AN/AN/AN/AN/A
Vericel Co. stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/A
3.00
2.74
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
0.57
6.20
5.95
Nutex Health Inc. stock logo
NUTX
Nutex Health
3.04
1.56
1.50
Vericel Co. stock logo
VCEL
Vericel
N/A
4.49
4.21

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
98.50%
Nutex Health Inc. stock logo
NUTX
Nutex Health
5.32%
Vericel Co. stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
31.63%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
1.30%
Nutex Health Inc. stock logo
NUTX
Nutex Health
48.48%
Vericel Co. stock logo
VCEL
Vericel
5.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
1,046214.25 million146.48 millionOptionable
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2,100127.67 million126.01 millionOptionable
Nutex Health Inc. stock logo
NUTX
Nutex Health
1,15049.72 million25.62 millionNot Optionable
Vericel Co. stock logo
VCEL
Vericel
31448.38 million45.86 millionOptionable

NEO, HIMS, VCEL, and NUTX Headlines

SourceHeadline
Knights of Columbus Asset Advisors LLC Purchases 112,169 Shares of Vericel Co. (NASDAQ:VCEL)Knights of Columbus Asset Advisors LLC Purchases 112,169 Shares of Vericel Co. (NASDAQ:VCEL)
marketbeat.com - April 19 at 1:38 PM
Vericel CorpVericel Corp
money.usnews.com - April 17 at 9:10 PM
Mutual of America Capital Management LLC Sells 21,706 Shares of Vericel Co. (NASDAQ:VCEL)Mutual of America Capital Management LLC Sells 21,706 Shares of Vericel Co. (NASDAQ:VCEL)
marketbeat.com - April 15 at 5:51 AM
Vericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking EvenVericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking Even
finance.yahoo.com - April 13 at 1:24 PM
Vericel Co. (NASDAQ:VCEL) Sees Large Increase in Short InterestVericel Co. (NASDAQ:VCEL) Sees Large Increase in Short Interest
marketbeat.com - April 12 at 10:31 AM
Vericel Co. (NASDAQ:VCEL) Shares Acquired by Conestoga Capital Advisors LLCVericel Co. (NASDAQ:VCEL) Shares Acquired by Conestoga Capital Advisors LLC
marketbeat.com - April 10 at 3:55 PM
Vericel Co. (NASDAQ:VCEL) Given Average Rating of "Buy" by BrokeragesVericel Co. (NASDAQ:VCEL) Given Average Rating of "Buy" by Brokerages
marketbeat.com - April 8 at 4:13 AM
Commit To Buy Vericel At $25, Earn 9% Annualized Using OptionsCommit To Buy Vericel At $25, Earn 9% Annualized Using Options
nasdaq.com - April 7 at 10:47 PM
Vericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 3,278 SharesVericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 3,278 Shares
insidertrades.com - March 30 at 7:35 AM
Vericel Co. (NASDAQ:VCEL) Stock Holdings Decreased by SG Americas Securities LLCVericel Co. (NASDAQ:VCEL) Stock Holdings Decreased by SG Americas Securities LLC
marketbeat.com - March 30 at 4:17 AM
Vericel (NASDAQ:VCEL) Sets New 1-Year High at $51.40Vericel (NASDAQ:VCEL) Sets New 1-Year High at $51.40
marketbeat.com - March 27 at 11:23 AM
Analyst Scoreboard: 5 Ratings For VericelAnalyst Scoreboard: 5 Ratings For Vericel
markets.businessinsider.com - March 27 at 1:54 AM
Truist Financial Reaffirms "Buy" Rating for Vericel (NASDAQ:VCEL)Truist Financial Reaffirms "Buy" Rating for Vericel (NASDAQ:VCEL)
marketbeat.com - March 26 at 9:35 AM
Vericel Co. (NASDAQ:VCEL) Shares Sold by Public Sector Pension Investment BoardVericel Co. (NASDAQ:VCEL) Shares Sold by Public Sector Pension Investment Board
marketbeat.com - March 20 at 4:17 AM
Dominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) StockDominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) Stock
insidertrades.com - March 17 at 5:42 AM
Vericel Co. (NASDAQ:VCEL) COO Sells $352,046.54 in StockVericel Co. (NASDAQ:VCEL) COO Sells $352,046.54 in Stock
insidertrades.com - March 14 at 9:39 AM
Vericel Co. (NASDAQ:VCEL) SVP Sells $367,852.95 in StockVericel Co. (NASDAQ:VCEL) SVP Sells $367,852.95 in Stock
insidertrades.com - March 12 at 4:46 AM
VCEL Oct 2024 50.000 callVCEL Oct 2024 50.000 call
ca.finance.yahoo.com - March 3 at 7:05 PM
US$52.07 - Thats What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These ResultsUS$52.07 - That's What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These Results
finance.yahoo.com - March 3 at 9:03 AM
Vericel Corporation (VCEL) Q4 2023 Earnings Call TranscriptVericel Corporation (VCEL) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 2 at 7:12 PM
Vericel Full Year 2023 Earnings: EPS Beats ExpectationsVericel Full Year 2023 Earnings: EPS Beats Expectations
finance.yahoo.com - March 2 at 8:15 AM
Buy Rating Affirmed for Vericel on Strong Financials and Growth ProspectsBuy Rating Affirmed for Vericel on Strong Financials and Growth Prospects
markets.businessinsider.com - March 1 at 12:06 PM
A Closer Look at 4 Analyst Recommendations For VericelA Closer Look at 4 Analyst Recommendations For Vericel
markets.businessinsider.com - March 1 at 12:06 PM
Vericel Corporation (NASDAQ:VCEL) Q4 2023 Earnings Call TranscriptVericel Corporation (NASDAQ:VCEL) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 1 at 12:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Hims & Hers Health logo

Hims & Hers Health

NYSE:HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.
NeoGenomics logo

NeoGenomics

NASDAQ:NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Nutex Health logo

Nutex Health

NASDAQ:NUTX
Nutex Health Inc. operates as a network of micro-hospitals. It operates through three segments: Hospital, Population Health Management, and Real Estate. The Hospital segment develops and operates a network of micro-hospitals, specialty hospitals and hospital outpatient departments which offers 24/7 care. The Population Health Management segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management. The Real Estate segment leases land and hospital building. It also provides healthcare and facility management services; and healthcare billing, coding, and collection services. In addition, the company offers healthcare services, including emergency room care, inpatient care, and behavioral health, as well as onsite imaging, such as CT scan, X-ray, MRI, ultrasound, etc.; certified and accredited laboratories; and onsite inpatient pharmacies. The company was founded in 2011 and is based in Houston, Texas.
Vericel logo

Vericel

NASDAQ:VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.